Financial news for ATRC dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for ATRC dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for ATRC dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for ATRC dated on 2020-05-13: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ATRC dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for ATRC dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ATRC dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for ATRC dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for ATRC dated on 2020-05-11: AtriCure Announces \$100M Common Stock Offering

Financial news for ATRC dated on 2020-05-11: ArtiCure Announcds \$100M Common Stock Offering

Financial news for ATRC dated on 2020-05-11: Oppenheimer Maintains Outperform on AtriCure, Raises Price Target to \$52

Financial news for ATRC dated on 2020-05-11: SVB Leerink Reiterates Outperform on AtriCure, Raises Price Target to \$55

Financial news for ATRC dated on 2020-05-08: AtriCure Reports Results From CONVERGE IDE Trial: 'study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure'

Financial news for ATRC dated on 2020-04-30: Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to \$45

Financial news for ATRC dated on 2020-04-29: AtriCure Q1 EPS \$(0.420) Misses \$(0.410) Estimate, Sales \$53.225M Miss \$55.500M Estimate

Financial news for ATRC dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for ATRC dated on 2020-04-28: JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to \$39

Financial news for ATRC dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for ATRC dated on 2020-04-13: Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to \$41

Financial news for ATRC dated on 2020-04-13: AtriCure Announces CONVERGE IDE Trial Results Accepted For Late-Breaking Clinical Trial Sessions At Annual Heart Rhythm Society (HRS) Meeting

Financial news for ATRC dated on 2020-04-09: AtriCure Inc Withdraws Its Previously Announced Financial Guidance For 2020

Financial news for ATRC dated on 2020-04-09: AtriCure Sees Prelim. Q1 Sales \$53.2M vs \$59.84M Est.

Financial news for ATRC dated on 2020-04-07: Benzinga's Top Upgrades, Downgrades For April 7, 2020

Financial news for ATRC dated on 2020-04-07: Oppenheimer Initiates Coverage On AtriCure with Outperform Rating, Announces Price Target to \$45

Financial news for ATRC dated on 2020-02-19: BTIG Research Maintains Buy on AtriCure, Raises Price Target to \$48

Financial news for ATRC dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For

Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for ATRC dated on 2020-02-19: Needham Maintains Buy on AtriCure, Raises Price Target to \$52

Financial news for ATRC dated on 2020-02-18: AtriCure Sees FY20 EPS \$(1.14)-\$(1.24) Vs. \$(1.09) Est.

Financial news for ATRC dated on 2020-02-18: AtriCure Q4 EPS \$(0.37) Beats \$(0.41) Estimate, Sales \$61.3M Beat \$59.5M Estimate

Financial news for ATRC dated on 2020-02-18: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ATRC dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for ATRC dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for ATRC dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for ATRC dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ATRC dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for ATRC dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ATRC dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for ATRC dated on 2020-02-10: Stocks That Hit 52-Week Highs On Monday

Financial news for ATRC dated on 2020-01-31: The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

Financial news for ATRC dated on 2020-01-30: Stocks That Hit 52-Week Highs On Thursday

Financial news for ATRC dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for ATRC dated on 2020-01-29: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ATRC dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for ATRC dated on 2020-01-28: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ATRC dated on 2020-01-24: Needham Maintains Buy on AtriCure, Raises Price Target to \$48

Financial news for ATRC dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for ATRC dated on 2020-01-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ATRC dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for ATRC dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ATRC dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for ATRC dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for ATRC dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for ATRC dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars

On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for ATRC dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ATRC dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for ATRC dated on 2020-01-13: AtriCure Sees Q4 Sales \$61.3M vs \$59.24M Est

Financial news for ATRC dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for ATRC dated on 2020-01-07: AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol

Financial news for ATRC dated on 2019-10-30: AtriCure Raises FY19 Sales Guidance From \$224M-\$228M To \$227M-\$229M vs \$227.45M Est.

Financial news for ATRC dated on 2019-10-30: AtriCure Q3 EPS \$(0.25) Beats \$(0.27) Estimate, Sales \$56.6M Beat \$55.23M Estimate

Financial news for ATRC dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for ATRC dated on 2019-09-06: 86 Biggest Movers From Yesterday

Financial news for ATRC dated on 2019-09-05: AtriCure shares trading lower following a negative report from Culpers Research.

Financial news for ATRC dated on 2019-09-05: 'AtriCure (ATRC): 57% Downside on a Maze of Highly Paid Doctors, Off-Label Device Usage, and Ongoing DOJ Investigation' Report From Culper Research

Financial news for ATRC dated on 2019-09-04: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ATRC dated on 2019-08-12: AtriCure Enters Into Definitive Agreement to Acquire SentreHEART; Upfront Payment of \$40M in Cash and Stock, Up to \$260M in Contingent Consideration

Financial news for ATRC dated on 2019-07-30: AtriCure Sees FY19 Sales \$224M-\$228M vs \$226.46M Est.

Financial news for ATRC dated on 2019-07-30: AtriCure Q2 EPS \$(0.17) Beats \$(0.18) Estimate, Sales \$58.9M Beat \$57.76M Estimate

Financial news for ATRC dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for ATRC dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for ATRC dated on 2019-04-25: AtriCure Sees FY19 Sales 222M-228M vs 225.84M Est.

Financial news for ATRC dated on 2019-04-25: AtriCure Q1 Adj, EPS \$(0.2) Beats \$(0.24) Estimate, Sales \$54M Beat \$52.36M Estimate

Financial news for ATRC dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for ATRC dated on 2019-04-23: AtriCure Reports First Patient Enrolled In DEEP IDE Trial Report

Financial news for ATRC dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for ATRC dated on 2019-04-12: JP Morgan Initiates Coverage On AtriCure with Overweight Rating, Announces \$37 Price Target

Financial news for ATRC dated on 2019-04-02: Benzinga's Top Upgrades, Downgrades For April 2, 2019

Financial news for ATRC dated on 2019-04-02: BTIG Research Upgrades AtriCure to Buy, Announces \$35

Financial news for ATRC dated on 2019-03-01: AtriCure Filing Shows Registration For Mixed Securities Offering, Including  $\sim 5.67M$  Shares Via Selling Shareholders

Financial news for ATRC dated on 2019-02-28: AtriCure Sees FY19 EPS (0.78)-(0.68) vs (0.58) Est., Sales 220M-228M vs 223.45M Est.

Financial news for ATRC dated on 2019-02-28: AtriCure Q4 EPS \$(0.09) Beats \$(0.17) Estimate, Sales \$52.89M Beat \$51.56M Estimate

Financial news for ATRC dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for ATRC dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for ATRC dated on 2019-02-19: AtriCure Reports The Society of Thoracic Surgeons Endorsed Co.'s Advanced Ablation Courses In US

Financial news for ATRC dated on 2019-01-07: AtriCure Sees FY2019 Sales \$220.0M-228.0M vs \$222.80M Est

Financial news for ATRC dated on 2019-01-07: AtriCure Sees FY2018 Sales  $$201.60M \ vs$   $$200.02M \ Est$ 

Financial news for ATRC dated on 2018-11-01: AtriCure Sees FY18 EPS (0.74)-(0.69) vs (0.69) Est., Sales 198M-201M vs 197.91M Est.

Financial news for ATRC dated on 2018-11-01: AtriCure, Inc. Q3 Adj. EPS \$(0.24) Misses \$(0.21) Estimate, Sales \$49.9M Beat \$47.72M Estimate

Financial news for ATRC dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for ATRC dated on 2018-10-09: Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to \$40

Financial news for ATRC dated on 2018-10-08: 46 Biggest Movers From Friday

Financial news for ATRC dated on 2018-10-05: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for ATRC dated on 2018-10-05: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

Financial news for ATRC dated on 2018-10-05: AtriCure Late Thursday Announced It Will Price Its 2.5M Share Common Stock Offering At \$30.75/\$Share

Financial news for ATRC dated on 2018-10-04: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

Financial news for ATRC dated on 2018-10-03: AtriCure Sees Q3 Sales  $\sim$ \$49.9M vs \$46.8M Estimate, Loss \$6M-\$7.5M

Financial news for ATRC dated on 2018-10-03: AtriCure Reports 2.5M Share Common Stock Offering

Financial news for ATRC dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for ATRC dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for ATRC dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for ATRC dated on 2018-09-20: Stocks Which Set New 52-Week High Yesterday, September 19th

Financial news for ATRC dated on 2018-09-20: The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

Financial news for ATRC dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for ATRC dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for ATRC dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic

Financial news for ATRC dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for ATRC dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for ATRC dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for ATRC dated on 2018-08-03: Stocks Which Set New 52-Week High Yesterday, August 2nd

Financial news for ATRC dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for ATRC dated on 2018-08-01: AtriCure Sees FY18 Sales \$193M-\$197M vs \$194.96M Est.

Financial news for ATRC dated on 2018-08-01: AtriCure Q2 EPS \$(0.01) Beats \$(0.23) Estimate, Sales \$51.8M Beat \$49.9M Estimate

Financial news for ATRC dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for ATRC dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for ATRC dated on 2018-07-20: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for ATRC dated on 2018-06-20: Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

Financial news for ATRC dated on 2018-06-15: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for ATRC dated on 2018-06-05: AtriCure, Baheal Group Establish Partnership and China Distribution Agreement

Financial news for ATRC dated on 2018-04-26: AtriCure Reiterates FY18 Sales Guidance of \$190M-\$196M vs \$193.79M Est.

Financial news for ATRC dated on 2018-04-26: AtriCure Q1 EPS \$(0.31) Misses \$(0.27) Est., Sales \$47M Beats \$45.46M Est.

Financial news for ATRC dated on 2018-02-28: AtriCure 10-K Shows Co. Received A Civil Investigative Demand From The Dept. Of Justice To Determine Whether The Co. Violated The False Claims Act

Financial news for ATRC dated on 2018-02-26: AtriCure Sees FY18 Sales \$190M-\$196M vs \$194.4M Est., Adj. EBITDA Positive

Financial news for ATRC dated on 2018-02-26: AtriCure Reports Q4 EPS (0.08) vs (0.27) In Same Qtr. Last Year, Adj. EBITDA Loss 300K, Sales 46.1M vs 45.4M Est.

Financial news for ATRC dated on 2018-02-26: AtriCure Q4 Earnings Outlook

Financial news for ATRC dated on 2018-01-08: Atricure Sees FY18 Sales  $\sim$ \$190M-\$196M vs \$195.8M Est.

Financial news for ATRC dated on 2018-01-08: AtriCure Sees Q4 Sales ~\$46.1M vs \$45.2M Est.; Sees FY17 Sales \$174.7M vs \$173.9M Est., Adj. EBITDA Loss \$4M-\$6M

Financial news for ATRC dated on 2017-11-01: AtriCure Sees Q4 Sales \$43.5M to \$46.5M vs \$43.44M Est.; Lowers FY 2017 Sales Guidance From \$177M-\$178M to \$172M-\$175M vs \$177M Est., Reaffirms FY 2017 EPS Guidance

Financial news for ATRC dated on 2017-11-01: AtriCure Q3 EPS \$(0.22) vs \$(0.24) Est., Sales \$42.2M vs \$43.4M Est.

Financial news for ATRC dated on 2017-07-27: AtriCure Sees FY17 Sales \$177M-\$178M vs \$175.95M Est.

Financial news for ATRC dated on 2017-07-27: AtriCure Reports Q2 EPS \$(0.21) vs \$(0.26) Est., Sales \$45.2M vs \$44.21M

Financial news for ATRC dated on 2017-07-18: AtriCure Names Salvatore Privitera CTO

Financial news for ATRC dated on 2017-05-04: AtriCure Sees FY17 EPS (1.04)-(0.94), Sales 175M-178M vs 175.5M Est.

Financial news for ATRC dated on 2017-05-04: AtriCure Reports Q1 EPS \$(0.32) vs \$(0.31) in Same Qtr. Last Year, Adj. EBITDA Loss \$3.7M, Sales \$41.3M vs \$40.3M Est.

Financial news for ATRC dated on 2017-04-25: AtriCure Reports AtriClip Systemk Surpassed 100K Units Sold Globally

Financial news for ATRC dated on 2017-03-07: Hearing Dealreporter Out With Report On Potential Sale Of Atricure

Financial news for ATRC dated on 2017-03-06: 15 Biggest Mid-Day Losers For Monday

Financial news for ATRC dated on 2017-03-06: Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital

Financial news for ATRC dated on 2017-03-06: BTIG Research Downgrades AtriCure To Neutral

Financial news for ATRC dated on 2017-02-28: AtriCure Reports Q4 EPS \$(0.27) vs \$(0.31) Est., Sales \$41.2M vs \$42.03M Est.

Financial news for ATRC dated on 2017-02-03: AtriCure Sees FY16 Sales \$155.1M vs \$156M Est.

Financial news for ATRC dated on 2017-02-03: AtriCure Reports Prelim. Q4 Sales  $\sim $41.2 \text{M} \text{ vs } $42 \text{M} \text{ Est.}$ 

Financial news for ATRC dated on 2017-01-09: AtriCure Q4 Revenue \$41.2M vs \$42.8M Est

Financial news for ATRC dated on 2016-11-17: Canaccord Genuity Medical Technology And Diagnostics Forum Today

Financial news for ATRC dated on 2016-11-15: Stifel Healthcare Conference Today

Financial news for ATRC dated on 2016-10-28: 20 Biggest Mid-Day Gainers For Friday

Financial news for ATRC dated on 2016-10-28: Mid-Morning Market Update: Markets Mostly Higher; Mastercard Beats Q3 Views

Financial news for ATRC dated on 2016-10-27: AtriCure Sees FY16 Rev. \$156-\$158M vs. Est. \$156M, EPS \$(1.16)-\$(1.10) vs. Est. \$(1.16)

Financial news for ATRC dated on 2016-10-27: AtriCure Reports Q3 EPS (0.21) vs. Est. (0.28), Rev. 38.3M vs. Est. 37.8M

Financial news for ATRC dated on 2016-08-04: AtriCure Sees FY16 EPS (1.22)-(1.12) vs. Est. (1.19)

Financial news for ATRC dated on 2016-08-04: Atricure Reports Q2 EPS (0.26) vs. Est. (0.30), Rev. 39.7M vs. Est. 39.8M

Financial news for ATRC dated on 2016-08-01: BMO Capital Highlights This Week's MedTech Earnings

Financial news for ATRC dated on 2016-06-21: AtriCure Reports First Patient Enrollment in FROST Cryoanalgesia Study

Financial news for ATRC dated on 2016-06-17: AtriCure Files \$150M Mixed Securities Shelf Offering

Financial news for ATRC dated on 2016-04-28: AtriCure Sees FY16 EPS (1.22)-(1.12) vs. Est. (1.19)

Financial news for ATRC dated on 2016-04-28: AtriCure Reports Q1 EPS \$(0.31) vs. Est. \$(0.32), Rev. \$35.9M vs. Est. \$35.7M

Financial news for ATRC dated on 2016-04-26: AtriCure Receives FDA Clearance for New AtriClip Device

Financial news for ATRC dated on 2016-04-12: AtriCure Reports 510(k) Clearance for cryoFORM Probe

Financial news for ATRC dated on 2016-03-29: Northland Securities Initiates Coverage on AtriCure at Outperform, Announces \$24.00 PT

Financial news for ATRC dated on 2016-02-23: AtriCure Reports Q4 EPS \$(0.36), Inline, Sales \$35.9M vs \$35.9M Est.

Financial news for ATRC dated on 2016-01-11: AtriCure Sees Q4 Sales \$35.90M vs \$35.90M Est

Financial news for ATRC dated on 2016-01-11: AtriCure Sees FY2015 Sales \$129.80M vs \$129.80M Est

Financial news for ATRC dated on 2015-11-10: Filing from AtriCure Shows Registration for Mixed Securities Shelf Offering, Including ~5.66M Common Shares

Financial news for ATRC dated on 2015-10-27: AtriCure Inline Q3 Loss \$0.22, Sales \$31.4M Vs Est \$31.38M; Sees FY 15 Rev \$129.5M-\$130.5M Vs Est \$128.96M; Sees FY 16 Revs Up 25%

Financial news for ATRC dated on 2015-10-05: Morning Market Losers

Financial news for ATRC dated on 2015-10-05: Must Watch Stocks for October 5, 2015

Financial news for ATRC dated on 2015-10-04: AtriCure Narrows 2015 View to Revenue of \$128M-\$129M vs \$127.63M Est

Financial news for ATRC dated on 2015-10-04: AtriCure to Acquire nContact for 3.7M Shares, \$8M in Cash, Up to \$50M in Contingent Consideration

Financial news for ATRC dated on 2015-09-29: Canaccord Analysts Recommend 'Aggressively Buying' AtriCure After Sell-Off

Financial news for ATRC dated on 2015-08-07: Benzinga's Top Initiations

Financial news for ATRC dated on 2015-08-07: BTIG Research Initiates Coverage on AtriCure at Buy, Announces \$34.00 PT

Financial news for ATRC dated on 2015-07-28: AtriCure Reports Q2 Sales 32.6M vs 30.5M Est., Loss of 0.18/Share vs Loss of 0.21/Share Est.; Raises FY15 Sales Guidance from 123.5M-125.5M to 127M-129M vs 124.5M Est.

Financial news for ATRC dated on 2015-04-29: Atricure Reports Q1 EPS -\$0.19 Vs Est -\$0.21, Sales \$29.9M vs Est \$28.59M

Financial news for ATRC dated on 2015-03-11: Dougherty & Company Initiates Coverage on AtriCure at Buy, Announces  $$25.00\ PT$ 

Financial news for ATRC dated on 2015-03-09: Needham Initiates Coverage on AtriCure at Buy, Announces \$21.00 PT

Financial news for ATRC dated on 2015-03-09: Needham Initiates Coverage on AtriCure at Buy, Announces \$21.00 PT

Financial news for ATRC dated on 2015-02-23: Atricure Reports Q4 Loss of 0.20/Share, Inline, Sales 29.4M vs 29M Est.; Sees FY15 Sales 122.5M-124.5M

Financial news for ATRC dated on 2015-01-22: Amended 13G: Thomson Horstmann Liquidates Stake In Atricure Inc.

Financial news for ATRC dated on 2015-01-14: AtriCure Inc Appoints Douglas Seith As COO AtriCure; Andy Wade To SVP

Financial news for ATRC dated on 2015-01-12: AtriCure Sees FY2015 Sales \$122.50M-124.50M

Financial news for ATRC dated on 2014-11-03: AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients

Financial news for ATRC dated on 2014-10-30: AtriCure, Inc. Reports Q3 EPS of (0.02) vs (0.17) Est; Revenue of 26.70M vs 25.59M Est

Financial news for ATRC dated on 2014-10-30: AtriCure Raises FY14 Revenue Outlook Above Estimates

Financial news for ATRC dated on 2014-10-09: AtriCure Completes Enrollment In Post Approval Study For The Synergy Ablation System

Financial news for ATRC dated on 2014-09-18: AtriCure Announces the Release of the AtriClip FLEX

Financial news for ATRC dated on 2014-05-30: Stifel Nicolaus Initiates Coverage on AtriCure, Inc. at Buy, Announces \$20.00 PT

Financial news for ATRC dated on 2014-05-30: Stifel Nicolaus Initiates Coverage on AtriCure, Inc. at Buy, Announces \$20.00 PT

Financial news for ATRC dated on 2014-05-21: AtriCure Announces AtriClip Patent

Financial news for ATRC dated on 2014-04-24: AtriCure, Inc. Reports Q1 EPS of \$(0.31) vs \$(0.22) Est; Revenue of \$24.80M vs \$23.36M Est

Financial news for ATRC dated on 2014-02-27: AtriCure, Inc. Reports Q4 EPS of \$(0.24) vs \$(0.14) Est; Revenue of \$21.90M vs \$21.16M Est

Financial news for ATRC dated on 2014-02-12: UPDATE: AtriCure Announces Commencement of Public Offering of Common Stock

Financial news for ATRC dated on 2014-01-15: Atricure Files \$150M Mixed Securities Shelf

Financial news for ATRC dated on 2014-01-09: AtriCure Announces Preliminary Revenue for Q4 \$21.9M; Guides FY 2014 Rev \$81.9M

Financial news for ATRC dated on 2013-12-19: AtriCure Announces Definitive Agreement to Acquire Estech for 2.1M Shares of AtriCure Stock and Up to \$26M in Additional Considerations

Financial news for ATRC dated on 2013-12-19: AtriCure Announces Definitive Agreement To Acquire Estech

Financial news for ATRC dated on 2013-10-29: AtriCure, Inc. Reports Q3 EPS of (0.13) vs (0.15) Est; Revenue of 20.10M vs 18.30M Est

Financial news for ATRC dated on 2013-09-03: AtriCure Appoints Scott Drake to Its Board of Directors

Financial news for ATRC dated on 2013-05-02: AtriCure, Inc. Reports Q1 EPS of \$(0.10) vs \$(0.11) Est; Revenue of \$19.40M vs \$18.62M Est; Reaffirms Outlook

Financial news for ATRC dated on 2013-01-16: Atricure Prices 3.475M Shares at \$7.25/Share

Financial news for ATRC dated on 2013-01-15: AtriCure Announces Commencement of Public Offering of Common Stock

Financial news for ATRC dated on 2013-01-07: AtriCure Sees Q4 Sales ~\$18.4M

Financial news for ATRC dated on 2012-11-16: UPDATE: Piper Jaffray Upgrades AtriCure to Overweight on New Management Confidence

Financial news for ATRC dated on 2012-11-16: Benzinga's Top Upgrades

Financial news for ATRC dated on 2012-11-16: Piper Jaffray Upgrades AtriCure from Neutral to Overweight, Raises PT from \$6 to \$10

Financial news for ATRC dated on 2012-11-01: AtriCure Names Michael Carrel President and Chief Executive Officer

Financial news for ATRC dated on 2012-11-01: AtriCure Reports Q3 EPS \$0.27 vs \$-0.12 Est; Revenues \$86.9M vs \$17.29M Est

Financial news for ATRC dated on 2012-08-06: Barrington Research Maintains AtriCure at Outperform, Lowers PT from \$17\$ to \$14

Financial news for ATRC dated on 2012-08-03: UPDATE: Piper Jaffray Downgrades AtriCure from Overweight to Neutral

Financial news for ATRC dated on 2012-08-03: Piper Jaffray Downgrades AtriCure from Overweight to Neutral, Lowers PT from \$12 to \$6

Financial news for ATRC dated on 2012-08-03: Benzinga's Top Downgrades

Financial news for ATRC dated on 2012-08-02: AtriCure Reports Q2 EPS \$-0.08 vs \$-0.08 Est; Revenues \$18.3M vs \$18.04M Est

Financial news for ATRC dated on 2012-07-03: UPDATE: Piper Jaffray Lowers PT to \$12 on AtriCure on Decreasing Demand for Microcap Stocks

Financial news for ATRC dated on 2012-07-03: Piper Jaffray Maintains AtriCure at Overweight, Lowers PT from \$14 to \$12

Financial news for ATRC dated on 2012-06-01: William Blair Upgrades AtriCure from Market Perform to Outperform

Financial news for ATRC dated on 2012-05-03: AtriCure Reports Q1 EPS \$-0.1 vs \$-0.14 Est; Revenues \$17.5M vs \$16.38M Est

Financial news for ATRC dated on 2012-02-28: Barrington Research Reiterates AtriCure

Financial news for ATRC dated on 2012-02-28: UPDATE: Piper Jaffray Raises Price Target on AtriCure to \$14

Financial news for ATRC dated on 2012-02-28: Piper Jaffray Upgrades AtriCure from Neutral to Overweight, Raises PT from \$11 to \$14

Financial news for ATRC dated on 2012-02-27: Earnings Scheduled For February 27

Financial news for ATRC dated on 2012-02-13: Earnings Scheduled For February 13

Financial news for ATRC dated on 2012-01-17: Piper Jaffray Gives Insight to Medical Technology Industry Overview

Financial news for ATRC dated on 2011-12-16: AtriCure's Synergy Ablation System Receives FDA Approval for the Treatment of Atrial Fibrillation

Financial news for ATRC dated on 2011-11-18: Canaccord Genuity Maintains Buy Rating and \$15.50 PT on AtriCure

Financial news for ATRC dated on 2011-11-02: Barrington Research Reaffirms Outperform on AtriCure

Financial news for ATRC dated on 2011-11-01: AtriCure Reports Q3 EPS (0.07) vs (0.08) Est; Revenues 15.2M vs 15.8M Est

Financial news for ATRC dated on 2011-10-27: Barrington Maintains Outperform Rating on AtriCure, \$10 PT AFter Positive Panel Vote

Financial news for ATRC dated on 2011-10-24: FDA Has Concerns About Study on Atricure's Ablation System

Financial news for ATRC dated on 2011-10-14: St. Jude Medical Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for ATRC dated on 2011-09-19: Barrington Research Reiterates AtriCure

Financial news for ATRC dated on 2011-09-19: FDA Panel to Review AtriCure's Synergy Ablation System on October 26

Financial news for ATRC dated on 2011-09-02: UPDATE: Piper Jaffray Lowers Price Target On AtriCure To \$11

Financial news for ATRC dated on 2011-09-02: Piper Jaffray Lowers PT On AtriCure To \$11

Financial news for ATRC dated on 2011-08-24: Benzinga's Top Upgrades

Financial news for ATRC dated on 2011-08-24: Morgan Keegan Upgrades AtriCure To Outperform, Lowers PT To \$13

Financial news for ATRC dated on 2011-08-03: Morgan Keegan Maintains Market Perform on AtriCure

Financial news for ATRC dated on 2011-07-18: Morgan Keenan Comments on AtriCure

Financial news for ATRC dated on 2011-07-01: AtriCure Files \$50M Mixed Security Shelf

Financial news for ATRC dated on 2011-02-16: AtriCure Reports Q4 EPS of \$0.00 vs. \$(0.08)

Financial news for ATRC dated on 2011-01-04: Barrington's Best Stock Picks for 2011

Financial news for ATRC dated on 2010-11-02: AtriCure Reports Third Quarter Revenue of \$14.5M

Financial news for ATRC dated on 2010-08-24: NASDAQ Stocks Hitting 52-Week Highs (ATRC, DTPI, LORL, RDCM)

Financial news for ATRC dated on 2010-06-15: Mid-Day Market Movers (ZANE, ATRC, DOVR, IFLG)

Financial news for ATRC dated on 2010-05-10: AtriCure (ATRC) Shares Rise On FDA News